{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:57:05Z","timestamp":1793224625437,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.cgh.2007.03.011","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T15:36:50Z","timestamp":1181230610000},"page":"818-828.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review"],"prefix":"10.1016","volume":"5","author":[{"given":"Alaa","family":"Rostom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Jolicoeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2007.03.011_bib1","first-page":"12","article-title":"Identification of patients at risk for gastropathy associated with NSAID use","volume":"20","author":"Fries","year":"1990","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.cgh.2007.03.011_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004836-199310000-00014","article-title":"NSAID-induced gastroduodenal damage: is prevention needed? a review and meta-analysis","volume":"17","author":"Stalnikowicz","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0889-8553(05)70253-3","article-title":"The risks and costs of upper gastrointestinal disease attributable to NSAIDs","volume":"25","author":"Smalley","year":"1996","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.cgh.2007.03.011_bib4","first-page":"6","article-title":"NSAID gastropathy: the second most deadly rheumatic disease? epidemiology and risk appraisal","volume":"28","author":"Fries","year":"1991","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.cgh.2007.03.011_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.1992.00400180139023","article-title":"The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease","volume":"152","author":"Bollini","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0895-4356(96)00361-7","article-title":"A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation","volume":"50","author":"McMahon","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cgh.2007.03.011_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","article-title":"Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Langman","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2007.03.011_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.315.7119.1333","article-title":"Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort Study","volume":"315","author":"MacDonald","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.03.011_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.28.5.527","article-title":"Nonsteroidal antiinflammatory drugs and life threatening complications of peptic ulceration","volume":"28","author":"Armstrong","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2007.03.011_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.7326\/0003-4819-109-5-359","article-title":"Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons","volume":"109","author":"Griffin","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib13","first-page":"1153","article-title":"Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use","volume":"82","author":"Larkai","year":"1987","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4","article-title":"The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs","volume":"41","author":"Maetzel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.03.011_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1503\/cmaj.050192","article-title":"Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario","volume":"175","author":"Mamdani","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.cgh.2007.03.011_bib16","series-title":"Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions\u2014technology report no 37","author":"Rostom","year":"2003"},{"key":"10.1016\/j.cgh.2007.03.011_bib17","series-title":"Health Canada","year":"2005"},{"key":"10.1016\/j.cgh.2007.03.011_bib18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?","volume":"332","author":"Kearney","year":"2006","journal-title":"Br Med J"},{"key":"10.1016\/j.cgh.2007.03.011_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2007.03.011_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimension of the methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.03.011_bib21","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1002\/sim.1091","article-title":"Approaches to heterogeneity in meta-analysis","volume":"20","author":"Petitti","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib22","unstructured":"FDA. Study 21: Celebrex. Available at: http:\/\/www.fda.gov\/cder\/foi\/adcomm\/98\/celebrex.htm. 1998."},{"key":"10.1016\/j.cgh.2007.03.011_bib23","unstructured":"FDA. Study 71: Celebrex. Available at: http:\/\/www.fda.gov\/cder\/foi\/adcomm\/98\/celebrex.htm. 1998."},{"key":"10.1016\/j.cgh.2007.03.011_bib24","unstructured":"FDA. Study 47: FDA review (ND21-341)\u2014Bextra. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-341_Bextra.htm. 2006."},{"key":"10.1016\/j.cgh.2007.03.011_bib25","unstructured":"FDA. Study 61: FDA drug review (ND21-341): Bextra. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-341_Bextra.htm. 2006."},{"key":"10.1016\/j.cgh.2007.03.011_bib26","unstructured":"FDA. Study 63: FDA drug review (ND21-341)\u2014Bextra. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-341_Bextra.htm. 2001."},{"key":"10.1016\/j.cgh.2007.03.011_bib27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2004.02118.x","article-title":"Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib","volume":"20","author":"Goldstein","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib29","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.03.011_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02735561","article-title":"Global analysis of gastrointestinal safety of a new NSAID, meloxicam","volume":"4","author":"Distel","year":"1996","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cgh.2007.03.011_bib31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1185\/030079905X43686","article-title":"The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs non-selective NSAIDs: an updated combined analysis","volume":"21","author":"Ramey","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2007.03.011_bib32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib33","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2007.03.011_bib34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.03.011_bib35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis: Rofecoxib Osteoarthritis Endoscopy Study Group","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.03.011_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.03.011_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gut.52.6.820","article-title":"Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2007.03.011_bib38","first-page":"1804","article-title":"Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis","volume":"31","author":"Hawkey","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-200210000-00011","article-title":"Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis","volume":"14","author":"Sikes","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/rheumatology\/keg359","article-title":"Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial","volume":"42","author":"Pavelka","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.cgh.2007.03.011_bib41","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1572-0241.2003.07598.x","article-title":"The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events","volume":"98","author":"Hunt","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2036.2003.01407.x","article-title":"Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib","volume":"17","author":"Hunt","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib43","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract"},{"key":"10.1016\/j.cgh.2007.03.011_bib44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","article-title":"Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis","volume":"19","author":"Kivitz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib45","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study\u2014a randomized controlled trial\u2014Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.03.011_bib46","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/rheumatology\/37.9.946","article-title":"Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis","volume":"37","author":"Dequeker","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib48","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/rheumatology\/37.9.937","article-title":"Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients: International MELISSA Study Group\u2014Meloxicam Large-scale International Study Safety Assessment","volume":"37","author":"Hawkey","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/030079904X20231","article-title":"Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies","volume":"21","author":"Schnitzer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2007.03.011_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079902125000282","article-title":"Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial","volume":"18","author":"Leung","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2007.03.011_bib51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-139-7-200310070-00005","article-title":"Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial","volume":"139","author":"Lisse","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1592\/phco.19.16.1269.30879","article-title":"Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib","volume":"19","author":"Zhao","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cgh.2007.03.011_bib53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/030097402320318431","article-title":"A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis","volume":"31","author":"Geusens","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study","volume":"119","author":"Singh","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib55","first-page":"436","article-title":"Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac","volume":"29","author":"Furst","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1063-4584(97)80024-6","article-title":"A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee","volume":"5","author":"Goei","year":"1997","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2007.03.011_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/35.suppl_1.39","article-title":"Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium","volume":"35","author":"Hosie","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00044011-199713040-00001","article-title":"Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study","volume":"13","author":"Hosie","year":"1997","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.cgh.2007.03.011_bib59","first-page":"282","article-title":"Efficacy and safety of meloxicam in patients with rheumatoid arthritis","volume":"24","author":"Lemmel","year":"1997","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2007.03.011_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/rheumatology\/35.suppl_1.35","article-title":"A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip","volume":"35","author":"Linden","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/030097498441146","article-title":"A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee","volume":"27","author":"Lund","year":"1998","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2007.03.011_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/35.suppl_1.22","article-title":"A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis","volume":"35","author":"Wojtulewski","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib63","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/archinte.160.19.2947","article-title":"Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial: the Meloxicam Osteoarthritis Investigators","volume":"160","author":"Yocum","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib64","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.03.011_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00124743-200004000-00002","article-title":"Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial","volume":"6","author":"Williams","year":"2000","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib66","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","article-title":"Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial","volume":"74","author":"Bensen","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2007.03.011_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF03351533","article-title":"A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis","volume":"13","author":"Truitt","year":"2001","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.cgh.2007.03.011_bib68","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis: Rofecoxib\/Ibuprofen Comparator Study Group","volume":"160","author":"Day","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib69","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","volume":"43","author":"Cannon","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.03.011_bib70","first-page":"2438","article-title":"Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib","volume":"26","author":"Ehrich","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib71","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","article-title":"The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis","volume":"21","author":"Schnitzer","year":"1999","journal-title":"Clinical Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib72","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis\u2014Osteoarthritis Studies Group","volume":"9","author":"Saag","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.287.1.64","article-title":"Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial","volume":"287","author":"Geba","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.03.011_bib74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2\u2013specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"Am J Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/030097401750065265","article-title":"Celecoxib versus diclofenac in the management of osteoarthritis of the knee","volume":"30","author":"McKenna","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00124743-200106000-00004","article-title":"COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study","volume":"7","author":"McKenna","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib77","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/joca.2001.0510","article-title":"Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen","volume":"10","author":"Makarowski","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.cgh.2007.03.011_bib78","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.cgh.2007.03.011_bib79","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/rheumatology\/41.9.1052","article-title":"Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis","volume":"41","author":"Gottesdiener","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.cgh.2007.03.011_bib80","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1185\/030079903125002469","article-title":"A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis","volume":"19","author":"Zacher","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2007.03.011_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2296-3-10","article-title":"A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]","volume":"3","author":"Collantes","year":"2002","journal-title":"BMC Family Practice"},{"key":"10.1016\/j.cgh.2007.03.011_bib82","first-page":"1623","article-title":"A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib83","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","article-title":"Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis","volume":"19","author":"Kivitz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.03.011_bib84","first-page":"1804","article-title":"Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis","volume":"31","author":"Hawkey","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib85","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2007.03.011_bib86","series-title":"Arthritis Drugs Advisory Committee meeting 12\/1\/1998","year":"1998"},{"key":"10.1016\/j.cgh.2007.03.011_bib87","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/030097402320817059","article-title":"Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis: results of two randomized treatment trials of six weeks duration","volume":"31","author":"Myllykangas-Luosujarvi","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib88","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/147323000102900602","article-title":"Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip","volume":"29","author":"Kivitz","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.cgh.2007.03.011_bib89","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/80.4.470","article-title":"Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Wiesenhutter","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2007.03.011_bib90","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1368-5031.2004.00398.x","article-title":"Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis","volume":"58","author":"Geusens","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cgh.2007.03.011_bib91","first-page":"589","article-title":"Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand","volume":"22","author":"Grifka","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cgh.2007.03.011_bib92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1185\/030079905X38196","article-title":"Efficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs placebo and celecoxib","volume":"21","author":"Lehmann","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2007.03.011_bib93","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.03.011_bib94","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","article-title":"Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial","volume":"127","author":"Laine","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.03.011_bib95","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2007.03.011_bib96","doi-asserted-by":"crossref","first-page":"14583","DOI":"10.1073\/pnas.251543298","article-title":"A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin","volume":"98","author":"Ouellet","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2007.03.011_bib97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.10738","article-title":"Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal","volume":"48","author":"Baigent","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.03.011_bib98","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cgh.2007.03.011_bib99","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","article-title":"Cyclooxygenase-2 expression and inhibition in atherothrombosis","volume":"24","author":"Cipollone","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507002844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507002844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:00:45Z","timestamp":1761541245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356507002844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1542356507002844"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2007.03.011","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2007.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2007.04.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}